Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis

被引:0
作者
Huang, Kaiyue [1 ,2 ]
Lv, Mi [1 ,2 ]
Zheng, Ting [1 ,2 ]
Wang, Fengyun [1 ]
Tang, Xudong [1 ]
Lv, Lin [1 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Inst Digest Dis, Beijing, Peoples R China
[2] China Acad Chinese Med Sci, Grad Sch, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
herbs; complementary treatment; placebo; irritable bowel syndrome; meta-analysis; DOUBLE-BLIND; ALTERNATIVE MEDICINE; PATHOPHYSIOLOGY; COMPLEMENTARY; EPIDEMIOLOGY; BENEFIT;
D O I
10.3389/fphar.2024.1475366
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim of the study To systematically evaluate the herbal placebo response in randomized controlled trials (RCTs) of herbal medicine on irritable bowel syndrome (IBS). Materials and methods We searched for RCTs with herbal placebo groups for IBS in PubMed, EMBASE, the Cochrane Library, the China National Knowledge Infrastructure (CNKI), the Wan Fang database and Sinomed database from 31 January 1994 to November 2023, and the quality of the literature was evaluated by the Cochrane risk of bias assessment criteria. The primary outcome indicators were response rate, abdominal pain and stool improvement rate, which were analyzed by single-group rate meta-analysis. Secondary outcomes were analyzed in subgroups based on diagnostic criteria, duration of treatment, subtype, research locations, placebo form, and presence of herbal ingredients to look for factors affecting respond rate. Results The study included 24 papers, involving a total of 2,596 patients. Of these, 1151 IBS patients were treated with the herbal placebo. The placebo response rate in IBS patients in the herbal placebo group was 37% (P < 0.01,I2 = 75%). A total of 287 patients in five studies were given the herbal placebo, and the improvement rate of abdominal pain was 29% (P = 0.83, I2 = 0%). Four studies enrolled a total of 212 patients with IBS who received herbal placebo, and the stool improvement rate was 46% (P = 0.02 < 0.05, I2 = 71%). The research locations and treatment duration were sources of heterogeneity (P < 0.05). Conclusion There is a significant herbal placebo response in patients with IBS. Different research locations and treatment durations are major sources of heterogeneity that may affect IBS patient response rates. The addition of a low dose of herbal ingredients when simulating an herbal placebo does not exaggerate the therapeutic effect of the placebo. There is a lack of uniformity and standardization in the preparation and evaluation of herbal placebos.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial
    Alt, Felix
    Chong, Pee-Win
    Teng, Emily
    Uebelhack, Ralf
    [J]. PHYTOTHERAPY RESEARCH, 2017, 31 (07) : 1056 - 1062
  • [2] Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial
    Bensoussan, A
    Talley, NJ
    Hing, M
    Menzies, R
    Guo, A
    Ngu, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18): : 1585 - 1589
  • [3] Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial
    Bensoussan, Alan
    Kellow, John E.
    Bourchier, Suzannah J.
    Fahey, Paul
    Shim, Lisa
    Malcolm, Allison
    Boyce, Philip
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) : 1946 - +
  • [4] Potential Benefit With Complementary and Alternative Medicine in irritable Bowel Syndrome: A Systematic Review and Meta-analysis
    Billings, Wade
    Mathur, Karan
    Craven, Hannah J.
    Xu, Huiping
    Shin, Andrea
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (08) : 1538 - +
  • [5] Global burden of irritable bowel syndrome: trends, predictions and risk factors
    Black, Christopher J.
    Ford, Alexander C.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (08) : 473 - 486
  • [6] Bosman M, 2021, LANCET GASTROENTEROL, V6, P459, DOI 10.1016/S2468-1253(21)00023-6
  • [7] Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea
    Brenner, Darren M.
    Sayuk, Gregory S.
    [J]. ADVANCES IN THERAPY, 2020, 37 (01) : 83 - 96
  • [8] Therapeutics, Placebo, and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research
    Brown, Jeremy R. Glissen
    Lembo, Anthony J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E921 - E922
  • [9] BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245
  • [10] Cai L. J., 2013, Chin. J. Traditional Chin. Med, V31, P1097